Lung Cancer Surgery Market Size is expected to amass considerable gains between 2022 and 2028, considering the high prevalence of lung cancer among the ever-increasing geriatric population, alongside the global burden of bronchus and trachea cancer. In addition, the rapid technological advances in cancer treatment and the growing death cases due to lung cancer will drive the demand for both non-small and small cell lung cancer surgery during the forecast period. Lung cancer refers to the growth of abnormal cells in the lung tissue. Attempts to cure the disease with surgery involve the removal of the tumor, the surrounding lung tissue, and lymph nodes in the tumor area. Surgery is considered the best treatment option for localized cancer, including carcinoid tumors.
Rising level of air pollution in developing economies and the increasing research and development activities on cancer treatment are some of the major trends bolstering the market outlook. The National Cancer Institute, for example, has been significantly offering funds to promote new cancer treatment and improve patient care, which in turn, could boost the acceptance of lung cancer removal surgery worldwide. As per the CDC’s report, cigarette smoking is linked to over 80%-90% of the lung cancer deaths in the U.S., thereby proliferating the overall business landscape. However, concerns regarding various complications after lung cancer surgery, including excessive bleeding and blood clot formation in the legs and lungs, may create roadblocks to the steady market growth in the coming years.
Minimally invasive surgeries will emerge as a prominent surgery segment for the market till2028. Segment growth can be credited to the increased reliance on this surgery type owing to low costs as compared to open chest surgery conducted via a thoracotomy. Its myriad other benefits, such as fewer complications, faster recovery, shorter hospital stay, and less blood loss, are also projected to amplify segment expansion during the forecast timeline.
The Europe lung cancer surgery market is set to depict a strong growth rate through 2028, led by the rising investment in cancer care across the region. In 2021, the UK Research and Innovation announced funding worth nearly $4.7 million to support the early diagnosis of lung cancer. According to Euractiv’s data, tobacco has become the largest health risk in the EU and is linked with 27% of all cancer types. Factors such as the high rate of tobacco smoking could, therefore, assert a positive influence on the regional share in the coming years.
Key players in the market include Trokamed GmbH, Scanlan International, Inc., Karl Storz GmbH, Ackermann Instrumente GmbH, Teleflex Incorporated, Olympus Corporation, Intuitive Surgical, Inc., Ethicon Us, LLC (Johnson & Johnson), AngioDynamics Inc., and Accuray Incorporated, among others. These firms are implementing various strategies like new product launches, mergers, and acquisitions to expand their business across the global market.
The ongoing coronavirus pandemic has posed an unprecedented challenge to the healthcare systems worldwide, especially the treatment of patients with cancer. Following the disease outbreak, several lung cancer patients delayed their return visit or regular anticancer treatment due to fear of disease transmission. Such significant impacts of the pandemic on oncological care have created a hindrance to the industry outlook over the past months. However, health concerns associated with the COVID-19 disease, which can lead to major damage on organs like lungs in the long term, may aid industry recovery over the coming years.
Market, By Product
Market, By Surgery
The above information is provided for the following regions and countries: